Clinical response, plasma levels and pharmacokinetics of desiramine in depressed in-patients

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 DOI:10.1016/0364-7722(81)90100-4

Pavel D Hrdina , Yvon D Lapierre

{"title":"Clinical response, plasma levels and pharmacokinetics of desiramine in depressed in-patients","authors":"Pavel D Hrdina , Yvon D Lapierre","doi":"10.1016/0364-7722(81)90100-4","DOIUrl":null,"url":null,"abstract":"<div><ul><li>1.1. Correlation between clinical response and plasma levels was investigated in seven patients with endogenous depression treated with 2×1 mg/kg/day of desipramine (DMI) for 21 days. Clinical response was measured by reduction in Hamilton Depression Rating Scale (HDRS) scores.</li><li>2.2. A beneficial effect of DMI was seen in five out of seven patients studied and was fully evident already one week after the beginning of treatment.</li><li>3.3. Great inter-individual differences were observed in DMI plasma levels both after a single dose and at ‘steady state’. The maximum plasma concentration after a single dose (Cmax) ranged between 19 and 179 ng/ml and the mean ‘steady state’ concentration between 65 and 240 ng/ml.</li><li>4.4. No significant correlation was found between HDRS scores and plasma levels of DMI; however, a plot of plasma levels and amelioration scores at the end (22nd day) of treatment was suggestive of a curvilinear relationship.</li><li>5.5. Post ‘steady state’ plasma disappearance half-lives of DMI calculation in four patients ranged from 11.5 to 34.3 hr (mean ± S.E.M. = 26.2 ± 5.0).</li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90100-4","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in neuro-psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0364772281901004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

Abstract

1.
1. Correlation between clinical response and plasma levels was investigated in seven patients with endogenous depression treated with 2×1 mg/kg/day of desipramine (DMI) for 21 days. Clinical response was measured by reduction in Hamilton Depression Rating Scale (HDRS) scores.
2.
2. A beneficial effect of DMI was seen in five out of seven patients studied and was fully evident already one week after the beginning of treatment.
3.
3. Great inter-individual differences were observed in DMI plasma levels both after a single dose and at ‘steady state’. The maximum plasma concentration after a single dose (C_max) ranged between 19 and 179 ng/ml and the mean ‘steady state’ concentration between 65 and 240 ng/ml.
4.
4. No significant correlation was found between HDRS scores and plasma levels of DMI; however, a plot of plasma levels and amelioration scores at the end (22nd day) of treatment was suggestive of a curvilinear relationship.
5.
5. Post ‘steady state’ plasma disappearance half-lives of DMI calculation in four patients ranged from 11.5 to 34.3 hr (mean ± S.E.M. = 26.2 ± 5.0).

查看原文本刊更多论文

住院抑郁症患者的临床反应、血浆水平及药代动力学

1.1. 对7例内源性抑郁症患者给予2×1 mg/kg/天地西帕明(DMI)治疗21天，观察其临床疗效与血浆水平的相关性。临床反应通过汉密尔顿抑郁评定量表(HDRS)得分的降低来衡量。在研究的7名患者中，有5名患者看到了DMI的有益效果，并且在治疗开始一周后就完全明显了。在单次给药后和“稳定状态”下，DMI血浆水平在个体间都存在很大差异。单次给药后的最大血浆浓度(Cmax)在19至179 ng/ml之间，平均“稳态”浓度在65至240 ng/ml之间。HDRS评分与血浆DMI水平无显著相关性;然而，在治疗结束时(第22天)的血浆水平和改善评分显示出曲线关系。4例患者DMI计算“稳态”后血浆消失半衰期为11.5 ~ 34.3小时(平均±S.E.M. = 26.2±5.0)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in neuro-psychopharmacology

自引率

0.00%

发文量